ZYME — Zymeworks Cashflow Statement
0.000.00%
Last trade - 00:00- $1.40bn
- $1.14bn
- $76.30m
- 55
- 20
- 99
- 61
Annual cashflow statement for Zymeworks, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -181 | -212 | 124 | -119 | -123 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 31.5 | 13.4 | 6.58 | 16.5 | 34.2 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -10.1 | 0.393 | 4.01 | -25.5 | -31 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -151 | -192 | 144 | -118 | -110 |
| Capital Expenditures | -6.26 | -13.3 | -13.1 | -4.08 | -3.07 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -37.2 | 158 | -40.7 | -203 | 41.8 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -43.4 | 145 | -53.8 | -207 | 38.8 |
| Financing Cash Flow Items | -0.113 | -0.47 | -0.596 | 49.8 | -0.174 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 309 | 8.01 | 109 | 81.8 | -20.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 114 | -40.2 | 199 | -243 | -91.5 |